Sterling Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Sterling Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$140K	Sell	1,061 -359	-25%	-$47.6K	﹤0.01%	1290
2025 Q4	$201K	Buy	1,420 +429	+43%	+$62.1K	﹤0.01%	1313
2025 Q3	$139K	Sell	991 -65	-6%	-$8.81K	﹤0.01%	1427
2025 Q2	$133K	Buy	1,056 +722	+216%	+$82.8K	﹤0.01%	1317
2025 Q1	$36.9K	Sell	334 -1,278	-79%	-$162K	﹤0.01%	1500
2024 Q4	$220K	Sell	1,612 -211	-12%	-$26.1K	﹤0.01%	1243
2024 Q3	$210K	Buy	+1,823	New	+$250K	﹤0.01%	1253
2018 Q4	–	Sell	-33,227	Closed	-$4.08M	–	904
2018 Q3	$4.08M	Hold	33,227	–	–	0.04%	273
2018 Q2	$3.26M	Hold	33,227	–	–	0.03%	301
2018 Q1	$2.76M	Buy	33,227 +16,919	+104%	+$1.43M	0.03%	335
2017 Q4	$1.26M	Buy	+16,308	New	+$1.11M	0.01%	536
2014 Q2	–	Sell	-18,625	Closed	-$300K	–	910
2014 Q1	$300K	Buy	+18,625	New	+$319K	﹤0.01%	859

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sterling Capital Management's NBIX Position: Q1 2026 in Review

Sterling Capital Management reduced its Neurocrine Biosciences (NBIX) stake by 25% in Q1 2026, selling an estimated $47.6K and leaving 1,061 shares worth $140K. The position accounts for ﹤0.01% of the portfolio, ranked #1290.

Sterling Capital Management first reported a position in NBIX in Q1 2014 and has held it in 12 quarters since. The position peaked at $4.08M in Q3 2018. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Sterling Capital Management held 1,061 shares of Neurocrine Biosciences worth $140K as of Q1 2026.
Sterling Capital Management sold 359 Neurocrine Biosciences shares in Q1 2026, an estimated $47.6K.
Neurocrine Biosciences made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #1290 holding.
Sterling Capital Management first reported a position in Neurocrine Biosciences in Q1 2014 and has held it in 12 quarters since.
Sterling Capital Management's Neurocrine Biosciences position peaked at $4.08M in Q3 2018.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.